Waldenström's macroglobulinemia

Best Practice and Research: Clinical Haematology

Volumn 18, Issue 4 SPEC. ISS., 2005, Pages 747-765

  Dimopoulos, Meletios A ^a   Anagnostopoulos, Athanasios ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

Diagnosis; Prognosis; Treatment; Waldenstr m's macroglobulinemia

Indexed keywords

ALPHA INTERFERON; AMYLOID PROTEIN; ANTHRACYCLINE; BETA 2 MICROGLOBULIN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CHLORAMBUCIL; CLADRIBINE; CLARITHROMYCIN; COLD AGGLUTININ; CRYOGLOBULIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; IMMUNOGLOBULIN M; MELPHALAN; MONOCLONAL ANTIBODY; MYELIN ASSOCIATED GLYCOPROTEIN; NITROSOUREA; NUCLEOSIDE ANALOG; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINCA ALKALOID; VINCRISTINE;

AGE DISTRIBUTION; AMYLOIDOSIS; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; BONE MARROW BIOPSY; CANCER CELL; CANCER INFILTRATION; CLINICAL FEATURE; CLINICAL TRIAL; CORRELATION ANALYSIS; CRYOGLOBULINEMIA; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; EYE DISEASE; GASTROINTESTINAL DISEASE; GERMINAL CENTER; HEMOLYTIC ANEMIA; HISTOPATHOLOGY; HUMAN; HYPERVISCOSITY SYNDROME; KIDNEY TUBULE DISORDER; LABORATORY TEST; LUNG DISEASE; LYMPHOCYTIC INFILTRATION; PERIPHERAL NEUROPATHY; PLASMAPHERESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SKIN DEFECT; SPLENECTOMY; SURVIVAL RATE; TREATMENT INDICATION; WALDENSTROEM MACROGLOBULINEMIA; WHOLE BODY RADIATION;

EID: 22144485535     PISSN: 15216926     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.beha.2005.01.028     Document Type: Review

References (100)

1. J. Waldenström Incipient myelomatosis or 'essential' hyperglobulinemia with fibrinogenopenia-a new syndrome? Acta Med Scand 117 1944 216-222
2. N.L. Harris E.S. Jaffe J. Diebold et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 Ann Oncol 10 1999 1419-1432
3. F.D. Groves L.B. Travis S.S. Devessa et al. Waldenström's macroglobulinemia: Incidence patterns in the United States, 1988-1994 Cancer 82 1998 1078-1081
4. M. McMaster Familial Waldenström's macroglobulinemia Semin Oncol 30 2003 146-152
5. M.S. Linet R.L. Humphrey E.S. Mehl et al. A case-control and family study of Waldenström's macroglobulinemia Leukemia 7 1993 1363-1369
6. F. Silvestri G. Barillari R. Fanin et al. Risk of hepatitis C virus infection, Waldenström's macroglobulinemia, and monoclonal gammopathies Blood 88 1996 1125-1126
7. S.A. Stone E.T. Lennette J.T. Newman et al. Serologic prevalence of antibody to human herpesvirus type 8 in patients with various monoclonal gammopathies Leuk Lymphoma 37 2000 197-203
8. N.L. Harris E.S. Jaffe H. Stein et al. A revised European-American classification of lymphoid neoplasms: A proposal from the International Lymphoma study Group Blood 84 1994 1361-1392
9. O. Tournillac D. Ditzel Santos A. Branagan et al. Excess bone marrow mast cells constituvely express CD154 (CD40 ligand) in Waldenström's macroglolbulinemia and may support tumor cell growth through CD154/CD40 pathway Proc Am Soc Clin Oncol 22 2004 565 (abstract 6555)
10. R.G. Owen S.L. Barrans S.J. Richards et al. Waldenström Macroglobulinemia. Development of diagnostic criteria and identification of prognostic factors Am J Clin Pathol 116 2001 420-428
11. J.F. San Miguel M.B. Vidriales E. Ocio et al. Immunophenotypic analysis of Waldenström's macroglobulinemia Semin Oncol 30 2003 187-195
12. J. Kriangkum B.J. Taylor M.J. Mant et al. The malignant clone in Waldenström's macroglobulinemia Semin Oncol 30 2003 132-135
13. S.S. Sahota F. Forconi C.H. Ottensmeier & F.K. Stevenson Origins of the malignant clone in typical Waldenström's macroglobulinemia Semin Oncol 30 2003 136-141
14. S.S. Sahota F. Forconi et al. C.H. Ottensmeier Typical Waldenström macroglobulinemia is derived from a B-cell arrested after cessation of somatic mutation but prior to isotype switch events Blood 100 2002 1505-1507
15. J. Kriangkum B.J. Taylor S.P. Treon et al. Clonotypic IgH VDJ sequence analysis in Waldenström's macroglobulinemia suggests an unusual B cell origin and expansion of polyclonal B cells in peripheral blood Blood 104 2004 2134-2142
16. A. Mansoor L.J. Medeiros D.M. Weber et al. Cytogenetic findings in lymphoplasmacytic lymphoma/Waldenström macroglobulinemia Am J Clin Pathol 116 2001 543-549
17. R. Schop W. Kuehl S. Van Wier et al Waldenström's macroglobulinemia neoplastic cells lack IgH translocations but have frequent 6q deletions Blood 100 2002 2996-3001
18. H. Avet-Loiseau R. Garand L. Lode et al. 14q32 translocations discriminate IgM multiple myeloma from Waldenström's macroglobulinemia Semin Oncol 30 2003 153-155
19. C.S. Mitsiades N. Mitsiades S.P. Treon & K.C. Anderson Proteomic analyses in Waldenström's macroglobulinemia and other plasma cell dyscrasias Semin Oncol 30 2003 156-160
20. C.S. Mitsiades N. Mitsiades P.G. Richardson et al. Novel biologically based therapies for Waldenström's macroglobulinemia Semin Oncol 30 2003 309-312
21. G. Merlini M. Farhangi & E.F. Osserman Monoclonal immunoglobulins with antibody activity in myeloma, macroglobulinemia and related plasma cell dyscrasias Semin Oncol 13 1986 350-365
22. M. Farhangi & G. Merlini The clinical implications of monoclonal immunoglobulins Semin Oncol 13 1986 366-379
23. M.A. Dimopoulos & R. Alexanian Waldenström's Macroglobulinemia Blood 83 1994 1452-1459
24. M.A. Dimopoulos P. Panayiotidis L.A. Moulopoulos et al. Waldenström's Macroglobulinemia: Clinical features, complications and management J Clin Oncol 18 2000 214-226
25. D. Crisp & W. Pruzanski B-cell neoplasms with homogeneous cold-reacting antibodies (cold agglutinins) Am J Med 72 1982 915-922
26. R.A. Kyle & J.P. Garton The spectrum of IgM monoclonal gammopathy in 430 cases Mayo Clin Proc 62 1987 719-731
27. U. Kallemuchikkal & P.D. Goveric Evaluation of cryoglobulins Arch Pathol Lab Med 123 1999 119-125
28. S.U. Persson H. Larsson & H. Odeberg How should blood rheology be measured in macroglobulinemia Scand J Clin Lab Invest 58 1998 669-676
29. H.C. Kwann & A. Bongu The hyperviscosity syndromes Semin Thromb Hemost 25 1999 199-208
30. M.A. Gertz & R.A. Kyle Hyperviscosity syndrome J Intens Care Med 10 1995 128-141
31. J.C. Brouet J.P. Clauvel F. Danon et al. Biologic and clinical significance of cryoglobulins Am J Med 57 1974 775-788
32. P.D. Gorevic H.J. Kassad Y. Levo et al. Mixed cryoglobulinemia:clinical aspects and long-term follow-up of 40 patients Am J Med 69 1980 287-308
33. W. Pruzanski & H. Shumak Biologic activity of cold reactive autoantibodies N Engl J Med 297 1977 538-542
34. W.F. Rosse J. Adams & G. Logue Hemolysis by complement and cold reaction antibody Am J Hematol 2 1977 259-270
35. N. Latov P.E. Braun R.B. Gross et al. Plasma cell dyscrasia and peripheral neuropathy: Identification of the myelin antigens that react with human paraproteins Proc Natl Acad Sci USA 78 1981 7139-7142
36. K. Dellagi P. Dupouey J.C. Brouet et al. Waldenström's macroglobulinemia and peripheral neuropathy: A clinical and immunologic study of 25 patients Blood 62 1983 280-285
37. A.H. Ropper & K.C. Gorson Neuropathies associated with paraproteinemia N Engl J Med 338 1998 1601-1607
38. T. Civit S. Coulbois F. Baylac et al. Waldenström's macroglobulinemia and cerebral lymphoplasmocytic proliferation: Bing and Neel syndrome. Apropos of a new case Neurochirurgie 43 1997 245-249
39. M.A. Dimopoulos G. Hamilos K. Zervas et al. Survival and prognostic factors after initiation of treatment in Waldenström's macroglobulinemia An Oncol 14 2003 1299-1305
40. M.A. Gertz R.A. Kyle & P. Noel Primary systemic amyloidosis: A rare complication of immunoglobulin M monoclonal gammopathies and Waldenström's macroglobulinemia J Clin Oncol 11 1993 914-920
41. L. Morel A. Basch F. Danon et al. Pathology of the kidney in Waldenström's macroglobulinemia N Engl J Med 283 1970 123-129
42. H.H. Fudenberg & G. Vinella Multiple myeloma and Waldenström's macroglobulinemia: Unusual presentations Sem Hematol 17 1980 63
43. F.D. Lindstrom J. Hed & S. Enestrom Renal pathology of Waldenström's macroglobulinemia with monoclonal antigromerular antibodies and nephrotic syndrome Clin Exp Immunol 41 1980 196-204
44. D.F. Moore L.A. Moulopoulos & M.A. Dimopoulos Waldenström's macroglobulinemia presenting as renal or peripheral mass: Clinical and radiographic features Leuk Lymphoma 17 1995 331-334
45. A. Fadil & D.E. Taylor The lung and Waldenström's macroglobulinemia South Med J 91 1998 681-685
46. M.C. Kyrtsonis T.P. Vassilakopoulos M.K. Angelopoulou et al. Waldenström's macroglobulinemia: Clinical course and prognostic factors in 60 patients Ann Hematol 80 2001 722-727
47. L. Schnitzler B. Schubert M. Boasson et al. Urticaire chronique, lesions osseuses, macroglobulinemie IgM: Maladie de Waldenström? Bull Soc Fr Derm Syph 81 1974 363-367
48. C.W. Hanke W.B. Steck W.F. Bergfeld et al. Cutaneous macroglobulinosis Arch Dermatol 116 1980 575-577
49. E. Morita K. Horiuchi S. Yamamoto et al. A case of acquired autoimmune bullous disease associated with IgM macroglobulinemia J Dermatol 26 1999 671-676
50. J.A. Rosenthal W.J. Curran &S.J. Schuster Waldenström's macroglobulinemia resulting from localized gastric lymphoplasmacytoid lymphoma Am J Hematol 58 1998 244-245
51. R.C. Tait P.K. Oagarah J.B. Houghton et al. Waldenström's macroglobulinemia secreting a paraprotein with lupus anticoagulant activity: Possible association with gastrointestinal tract disease and malabsorption Clin Pathol 46 1993 678-680
52. C.M. Knox J.G. Wong E.L. Howes et al. Vitreitis and Waldenström's macroglobulinemia Am J Ophthalmol 126 1998 314-315
53. R.G. Owen S.P. Treon A. Al-Katib et al. Clinicopathological definition of Waldenström's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia Semin Oncol 30 2003 110-115
54. R. Alexanian D. Weber K. Delasalle et al. Asymptomatic Waldenström's macroglobulinemia Semin Oncol 30 2003 206-210
55. R.A. Kyle T.M. Therneau S.V. Rajkumar et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance Blood 102 2003 3759-3764
56. G.A. Pangalis M.C. Kyrtsonis F.N. Kontopidou et al. Differential diagnosis of Waldenström's macroglobulinemia from other low-grade B-cell lymphoproliferative disorders Semin Oncol 30 2003 201-205
57. R.A. Kyle S.P. Treon R. Alexanian et al. Prognostic markers and criteria to initiate therapy in Waldenström's macroglobulinemia: Consensus panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia Semin Oncol 30 2003 116-120
58. D. Weber S.P. Treon C. Emmanouilides et al. Uniform response criteria in Waldenström's macroglobulinemia: Consensus Panel recommendations from the Second International Workshop on Waldenström's macroglobulinemia Semin Oncol 30 2003 127-131
59. R.A. Kyle P.R. Greipp M.A. Gertz et al. Waldenström's macroglobulinemia: A prospective study comparing daily with intermittent oral chlorambucil Br J Haematol 108 2000 737-742
60. J.M. Foran A.Z. Rohatiner B. Coiffier et al. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia and mantle cell lymphoma J Clin Oncol 17 1999 546-553
61. M.V. Dhodapkar J.L. Jacobson M.A. Gertz et al. Prognostic factors and response to fludarabine therapy in Waldenström's macroglobulinemia: an update of a US Intergroup Trial (SWOG 5903) Semin Oncol 30 2003 220-225
62. M.A. Dimopoulos H. Kantarjian D. Weber et al. Primary therapy of Waldenström's macroglobulinemia with 2-chroradeoxyadenosine J Clin Oncol 12 1994 2694-2698
63. M.A. Fridrik G. Jager C. Baldinger et al. First-line treatment of Waldenström's macroglobulinemia with cladribine Ann Hematol 74 1997 7-10
64. K. Lewandowski S.M. Zavcha M. Bieniaszewska et al. 2-Chlorodeoxyadenosine treatment of Waldenström's macroglobulinemia-the analysis of own experience and review of the literature Med Sci Monit 6 2000 740-745
65. A. Delannoy E. Van de Neste J.L. Michaux et al. Cladribine for Waldenström's macroglobulinemia Br J Haematol 104 1999 933
66. A. Hampshire & A. Saven Update of bolus administration of cladribine in the treatment of Waldenström's macroglobulinemia Blood 102 2003 402a
67. M.A. Dimopoulos S. O'Brien H. Kantarjian et al. Fludarabine therapy in Waldenström's macroglobulinemia Am J Med 95 1993 49-52
68. V. Leblond T. Ben-Othman E. Deconinck et al. Activity of fludarabine in previously treated Waldenström's macroglobulinemia: A report of 71 cases. Group Cooperatif Macroglobulinemie J Clin Oncol 16 1998 2060-2064
69. V. Leblond V. Levy F. Maloisel et al. Multicenter, randomized comparative trial of fludarabine and the combination of cyclophosphamide-doxorubicin-prednisone in 92 patients with Waldenström macroglobulinemia Blood 98 2001 2640-2644
70. M.A. Dimopoulos D. Weber K.B. Delasalle et al. Treatment of Waldenström's macroglobulinemia resistant to standard therapy with 2-Chlorodeoxyadenosine: Identification of prognostic factors Ann Oncol 6 1995 49-52
71. D.C. Betticher S.F. Hsu Schimitz D. Ratschiller et al. Cladribine (2-CDA) given as subcutaneous bolus injection is active in pretreated Waldenström's macroglobulinemia. Swiss Group for Clinical Cancer Research Br J Haematol 99 1997 358-363
72. M.A. Dimopoulos D.M. Weber H. Kantarjian et al. 2-Chlorodeoxyadenosine therapy of patients with Waldenström macroglobulinemia previously treated with fludarabine Ann Oncol 5 1994 288-289
73. D.C. Case T.J. Ervin & M.A. Boyd Long-term results and disease characteristics of patients with Waldenström's macroglobulinemia treated with the M-2 protocol Blood 82 1993 561a
74. M.T. Petrucci G. Avvissati M. Tribalto et al. Waldenström's macroglobulinemia: Results of a combined oral treatment in 34 newly diagnosed patients J Intern Med 226 1989 443-447
75. D.M. Weber M.A. Dimopoulos K. Delasalle et al. 2 cholorodeoxyadenosine alone and in combination for previously untreated Waldenström's macroglobulinemia Semin Oncol 30 2003 243-247
76. M.A. Dimopoulos G. Hamilos E. Efstathiou et al. Treatment of Waldenström's macroglobulinemia with the combination of fludarabine and cyclophosphamide Leuk Lymphoma 44 6 2003 993-996
77. R. Desikan M. Dhodapkar D. Siegel et al. High-dose therapy with autologous haemopoietic stem cell support for Waldenström's macroglobulinemia Br J Haematol 105 1999 993-996
78. A. Anagnostopoulos M.A. Dimopoulos A. Aleman et al. High-dose chemotherapy followed by stem cell transplantation in patients with resistant Waldenström's macroglobulinemia Bone Marrow Transplant 27 2001 1027-1029
79. O. Tournillac V. Leblond R. Tabrizi et al. Transplantation in Waldenström's macroglobulinemia - The French experience Semin Oncol 30 2003 291-296
80. J.C. Byrd C.A. White B. Link et al. Rituximab therapy in Waldenström's macroglobulinemia: Preliminary evidence of clinical activity Ann Oncol 10 1999 1525-1527
81. J.M. Foran A.Z. Rohatiner D. Cunningham et al. European phase II study of rituximab (chrmeric anti-CD20 monoclonal antibody for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma J Clin Oncol 18 2000 317-324
82. S.P. Treon D.B. Agus B. Link et al. CD-20 directed antibody-mediated immunotherapy induces responses and facilitates hematologic recovery in patients with Waldenström's macroglobulinemia J Immunother 24 2001 272-279
83. M.A. Dimopoulos C. Zervas A. Zomas et al. Treatment of Waldenström's macroglobulinemia with rituximab J Clin Oncol 20 2002 2327-2333
84. M.A. Gertz M. Rue E. Blood et al. Rituximab for Waldenström's macroglobulinemia (E3A98): An ECOG phase II pilot study for untreated or previously treated patients Blood 102 2003 148a (abstract 508)
85. S.P. Treon C.A. Emmanouilides E. Kimby et al. Pre-therapy serum IgM levels predict clinical response to extended rituximab in Waldenström's macroglobulinemia Blood 100 2002 813a (abstract 3211)
86. M.A. Dimopoulos K. Zervas A. Zomas et al. Treatment of Waldenström's macroglobulinemia with rituximab: Prognostic factors for response and progression Blood 102 2003 448a (abstract 1636)
87. I.M. Ghobrial R. Fonseca P.R. Greipp et al. The initial 'flare' of IgM level after rituximab therapy in patients diagnosed with Wladenstrom Macroglobulinemia: An Eastern Cooperative Oncology Group Study Blood 102 2003 448a (abstract 1637)
88. S.P. Treon P. Wasi C. Emmanouilides et al. Combination therapy with rituximab and fludarabine is highly active in Waldenström's macroglobulinemia Blood 100 2002 211a (abstract 794)
89. B. Rotoli A. De Renzo F. Frigeri et al. A phase II trial on alpha-interferon effect in patients with monoclonal IgM gammopathy Leuk Lymphoma 13 1994 463-469
90. E. Legouffe J.F. Rossi J.P. Laporte et al. Treatment of Waldenström's macroglobulinemia with very low doses of alpha interferon Leuk Lymphoma 19 1995 337-342
91. M.A. Dimopoulos C. Tsatalas A. Zomas et al. Treatment of Waldenström's macroglobulinemia with single-agent thalidomide or with the combination of clarithromycin, thalidomide and dexamethasone Semin Oncol 30 2003 265-269
92. M. Coleman J. Leonard L. Lyons et al. Treatment of Waldenström's macroglobulinemia with clarithromycin, low-dose thalidomide and dexamethasone Semin Oncol 30 2003 270-274
93. J.C. Humphrey & C. Lockard Durable complete remission of macroglobulinemia after splenectomy Am J Hematol 48 1995 262-266
94. W.F. Clark G.A. Rock N. Buskard et al. Therapeutic plasma exchange: An update from the Canadian Apheresis Group Ann Intern Med 131 1999 453-462
95. N. Latov Prognosis of neuropathy with monoclonal gammopathy Muscle Nerve 23 2000 150-152
96. P.G. Gobbi R. Bettini C. Montecucco et al. Study of prognosis in Waldenström's macroglobulinemia: A proposal for a simple binary classification with clinical and investigational utility Blood 83 1994 2939
97. P. Morel M. Monconduit D. Jacomy et al. Prognostic factors in Waldenström macroglobulinemia: A report on 232 patients with the description of a new scoring system and its validation on 253 other patients Blood 2000 852-858
98. R. Garcia-Sanz S. Montolo A. Torrequebrada et al. Waldenström macroglobulinemia: Presenting features and out come in a series with 217 cases Br Haematol 155 2001 575-582
99. G. Merlini L. Baldini C. Broglia et al. Prognostic factors in Waldenström's macroglobulinemia Semin Oncol 30 2003 211-215
100. I.M. Ghobrial R. Fonseca M.A. Gertz et al. Prognostic factors, disease specspecific and overall mortality in 506 patients diagnosed with WalWaldenström macroglobulinemia BloodQ 102 2003 934a (abstract 3477)